First, we compared AKT protein expression in samples from patients with FLT3-ITD AML pre- and post-treatment with mitoxantrone-liposomes, and found increased expression of the AKT protein post-treatment (Fig. 3c-d). This evidence concerns the gene FLT3 and acute myeloid leukemia.